Skip to main content

Table 3 Vaccine formulations to be administered in OptImms

From: Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) — a protocol for two parallel, open-label, randomised controlled trials

Manufacturer

Vaccine

Contents

Serum Institute of India

DTwP-HBV-Hib

Diphtheria toxoid ≥ 30 IU,

Tetanus toxoid ≥ 40 IU

B. Pertussis (whole cell) ≥ 4 IU, Hep B surface antigen (rDNA) 10mcg,

Purified capsular polysaccharide of Hib (PRP)

conjugated to tetanus toxoid (carrier protein) 10mcg

Bharat-Biotech

Typhoid conjugate

Purified Vi-capsular polysaccharide of S. Typhi Ty2 conjugated to Tetanus Toxoid 25 µg

Sanofi Pasteur

Yellow fever

Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU produced in specified pathogen-free chick embryos

Back to article page

Trials

ISSN: 1745-6215